WuXi Vaccines (Hong Kong) Ltd. said it has partnered with an undisclosed global company and signed a 20-year vaccine manufacturing contract valued at about $3 billion.
The China-based joint venture — owned by WuXi Biologics (Cayman) Inc. and Shanghai Hile Bio-Technology Co. Ltd. — will build a manufacturing facility that includes drug substance manufacturing, drug product manufacturing, research labs and quality control labs.
“This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines,” Chairman Chris Chen stated in a news release dated Feb. 18.
WuXi Vaccine’s new manufacturing facility is expected to begin operations in 2022.
In November 2019, the contract development and manufacturing organization said it received an investment valued at $240 million to build a vaccine manufacturing facility in Ireland. The facility is located within WuXi Biologics’ campus and is expected to begin manufacturing in 2021.
